Literature DB >> 9044843

Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes.

J R Duncan1, M T Stephenson, H P Wu, C J Anderson.   

Abstract

To better understand the factors that govern the target-to-background ratios of 111In-diethylenetriaminepentaacetic acid (DTPA) polypeptides, we studied 111In-DTPA-octreotide and a model nontargeted compound, 111In-DTPA-poly(D)lysine-biotin. We evaluated the fate of 111In-DTPA-octreotide after it localizes in somatostatin receptor-positive tissues and sought to determine why such a large fraction of these and other 111In-DTPA-polypeptides accumulate in the liver and kidneys. Biodistribution studies in rats with an implanted pancreatic adenocarcinoma demonstrated rapid accumulation of 111In-DTPA-octreotide in the pancreas and tumor. Indium-111 also accumulated in the liver and kidneys. Subcellular fractionation of the liver, kidneys, tumor, and pancreas showed that the majority of the radioactivity copurified with lysosomal enzymes. Even at 1 h, little radioactivity was found in the fractions containing a cell surface enzyme. This suggests that in each tissue, the 111In-DTPA-octreotide was rapidly shuttled from the cell surface to lysosomes. In the liver, hepatocyte lysosomes were separated from sinusoidal and Kupffer cell lysosomes by administering chloroquine prior to sacrifice. This density shift experiment indicated that 111In-DTPA-octreotide accumulated predominantly in hepatocyte lysosomes. A low molecular weight 111In-DTPA-poly(D)lysine-biotin compound was synthesized, and biodistribution studies showed substantial renal accumulation. The poly(D)lysine backbone conferred resistance to degradation, and this fact allowed determination of the distribution of this compound at the cellular level using an antibiotin antibody and immunohistochemical techniques. These experiments, as well as subcellular fractionation studies, demonstrated that the 111In-DTPA-poly(D)lysine-biotin compound accumulated in the lysosomes of proximal renal tubular cells. These results indicate that lysosomes play a critical role in the cellular physiology of radiolabeled polypeptides. Using these data, we propose a comprehensive model that summarizes the factors that govern the target to background ratios of radiolabeled polypeptides.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9044843

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  [123I]Mtr-TOCA, a radioiodinated and carbohydrated analogue of octreotide: scintigraphic comparison with [111In]octreotide.

Authors:  Alexander Stahl; Günther Meisetschläger; Margret Schottelius; Kjerstin Bruus-Jensen; Ingo Wolf; Klemens Scheidhauer; Markus Schwaiger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-09       Impact factor: 9.236

2.  Dosimetry of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy.

Authors:  Irina Velikyan; Thomas N Bulenga; Ramkumar Selvaraju; Mark Lubberink; Daniel Espes; Ulrika Rosenström; Olof Eriksson
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

3.  Somatostatin receptor subtype 2-mediated scintigraphy and localization using (99m)Tc-HYNIC-Tyr(3)-octreotide in human hepatocellular carcinoma-bearing nude mice.

Authors:  Yong Li; Jian-Ming Si; Jun Zhang; Jin Du; Fan Wang; Bing Jia
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

4.  [(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate.

Authors:  Theodosia Maina; Berthold A Nock; Paul Cordopatis; Bert F Bernard; Wout A P Breeman; Arthur van Gameren; Ria van den Berg; Jean-Claude Reubi; Eric P Krenning; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-28       Impact factor: 9.236

5.  111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.

Authors:  Astrid Capello; Eric Krenning; Bert Bernard; Jean-Claude Reubi; Wout Breeman; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07-15       Impact factor: 9.236

6.  A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues.

Authors:  Rogier P J Schroeder; Cristina Müller; Suzanne Reneman; Marleen L Melis; Wout A P Breeman; Erik de Blois; Chris H Bangma; Eric P Krenning; Wytske M van Weerden; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-25       Impact factor: 9.236

7.  Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an alphavbeta6-specific peptide.

Authors:  Sven H Hausner; David L Kukis; M Karen J Gagnon; Catherine E Stanecki; Riccardo Ferdani; John F Marshall; Carolyn J Anderson; Julie L Sutcliffe
Journal:  Mol Imaging       Date:  2009 Mar-Apr       Impact factor: 4.488

8.  Replacing 99mTc with 111In improves MORF/cMORF pretargeting by reducing intestinal accumulation.

Authors:  Guozheng Liu; Dengfeng Cheng; Shuping Dou; Xiangji Chen; Minmin Liang; P Hendrik Pretorius; Mary Rusckowski; Donald J Hnatowich
Journal:  Mol Imaging Biol       Date:  2009-03-27       Impact factor: 3.488

Review 9.  Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues.

Authors:  Edgar J Rolleman; Marleen Melis; Roelf Valkema; Otto C Boerman; Eric P Krenning; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-14       Impact factor: 9.236

10.  Easy access to heterobimetallic complexes for medical imaging applications via microwave-enhanced cycloaddition.

Authors:  Nicolas Desbois; Sandrine Pacquelet; Adrien Dubois; Clément Michelin; Claude P Gros
Journal:  Beilstein J Org Chem       Date:  2015-11-17       Impact factor: 2.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.